The Lynx Group


One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read More

Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution.
Read More

Value-Based Agreements: State of the Market Report
An industry wide ecosystem report and survey was conducted with over 200 Subject Matter Experts, Key Opinion Leaders, Academic Cancer Care Centers, Community Cancer Providers, Revenue Cycle Management Companies, Pharmaceutical Manufacturers, National and Regional Insurance Companies, Personalized Medicine, Employers, Government Agencies, and Policy Influencers.
Read More

Headwinds and Tailwinds Ahead for Value-Based Agreements
Panel discussion by key subject matter experts on the path ahead in terms headwinds and tailwinds for the advancement of value-based agreements. The panel will focus on the collaborative opportunities for participation by pharmaceutical manufacturers, healthcare innovators, diagnostic, and other telehealth and artificial intelligence technologies.
Read More

The Role of the Patient in Value-Based Agreements
Typically, value-based agreements tend to be between pharmaceutical companies and insurance companies, and we will continue to see the evolution of these to include other key players such as employers, health systems, etc. But what about the patients?
Read More

Transitioning from Volume-Based Discounts to Value-Based Agreements
Pharmaceutical and biotech innovators will face much different healthcare market dynamics on the path to commercialization ahead. Pharmaceutical innovators, providers and payer partners will have to be prepared to adapt and overcome the legacy challenges to participate in value-based agreements. Engaging with providers as partners vs. merely customers is also new.
Read More

Transforming Healthcare Delivery with Artificial Intelligence
Artificial Intelligence could significantly reduce inefficiency in healthcare, improve patient flow and experience, and enhance caregiver experience and patient safety through the care pathway. It can even get life-saving treatments to market faster.
Read More

The Practical Framework for Value-Based Agreements
This panel discussion is on the approach MassHealth took in creating value-based agreements. MassHealth had the legislative authority to directly negotiate with pharmaceutical manufacturers based on the proposed value of the drug. This presentation will review the path MassHealth took from planning, negotiating, and implementing supplemental value-based agreements.
Read More

Access Challenges for Medicaid Patients
This session will discuss access challenges for Medicaid patients.
Read More

Pediatrics and the Future in Cancer Care
This session will take a deeper dive of pediatrics and the future in cancer care.
Read More

Page 1 of 326

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: